{"ok":true,"entity":{"id":"abbvie","name":"AbbVie","entityType":"company","officialName":"AbbVie Inc.","canonicalName":"AbbVie","displayName":"AbbVie","category":"大手製薬企業","shortDescription":"米国イリノイ州に本社を置く研究開発型のバイオ医薬品企業。2013年にAbbott Laboratoriesから分社独立し、免疫疾患・腫瘍・神経科学・眼科・美容医療（Allergan Aesthetics）を重点領域とする。Humiraの独占期間終了後は、SkyriziとRinvoqを中核とする免疫疾患ポートフォリオへ移行している。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.abbvie.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["免疫疾患","腫瘍","神経科学","美容医療","Skyrizi","Rinvoq"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-05-001"]}